Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838870 | 0.88 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL17853481 | 0.87 | NR1D1 (0.53) | STSNR1D1GPR119HTTSMN1; SMN2 | |
| SCHEMBL17838815 | 0.87 | MEN1 (0.53) | STSNR1D1GPR119HTTSMN1; SMN2 | |
| SCHEMBL17838865 | 0.82 | STS (0.50) | STSNR1D1GPR119HTTSMN1; SMN2 | |
| SCHEMBL17838854 | 0.80 | PPARA (0.39) | MEN1KMT2ASCN9A | |
| SCHEMBL17838877 | 0.79 | MEN1 (0.48) | STSNR1D1GPR119HTTSMN1; SMN2 | |
| SCHEMBL16097143 | 0.79 | KMT2A (0.62) | STSGPR119NPSR1MEN1KMT2A | |
| SCHEMBL17838899 | 0.77 | CHIT1 (0.55) | — | |
| SCHEMBL655030 | 0.77 | NR1D1 (0.55) | STSNR1D1GPR119HTTSMN1; SMN2 | |
| SCHEMBL17838866 | 0.77 | MEN1 (0.49) | STSNR1D1GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233832-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-11-20 | — | — | EP | disclosed |
| EP-3233832-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-11-20 | — | — | EP | disclosed |
| EP-3233832-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS S.A. (PL) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368894-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-12-22 | — | — | US | disclosed |
| US-20160368894-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-12-22 | — | — | US | disclosed |
| US-20160368894-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-12-22 | — | — | US | disclosed |
| US-9440953-B2 | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-09-13 | — | — | US | disclosed |
| US-9440953-B2 | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-09-13 | — | — | US | disclosed |
| US-9440953-B2 | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-09-13 | — | — | US | disclosed |
| WO-2016099311-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016099311-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176843-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-06-23 | — | — | US | disclosed |
| US-20160176843-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-06-23 | — | — | US | disclosed |
| US-20160176843-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176843-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | CHIA, CHIT1, CMA1 | STS 448/4885NR1D1 3804/4885GPR119 2338/4885 |
| US-20160368894-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS | CHIA, CHIT1, CMA1 | STS 448/4885NR1D1 3804/4885GPR119 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.